Scpharmaceutical Stock Price, News & Analysis

scPharmaceuticals Inc. (Nasdaq: SCPH) announced that CEO John Tucker will participate in the 12th Annual LifeSci Partners Corporate Access Event on January 9-10, 2023, in San Francisco. The company focuses on developing products to optimize infused therapies, improve patient care, and reduce healthcare costs. Their key initiatives aim to facilitate outpatient treatment for acute conditions, particularly in heart failure and infectious diseases through subcutaneous self-administration of IV-strength therapies. More details regarding the event can be found on their website.

scPharmaceuticals Inc. (Nasdaq: SCPH) announced a public offering of 6,620,000 shares of common stock at $5.25 each, alongside a prefunded warrant for 2,905,000 additional shares at $5.249 each. The total gross proceeds are projected at approximately $50 million, prior to expenses. The offering is set to close on November 25, 2022, pending customary conditions. SVB Securities and Cowen are leading the offering. The securities are registered under a shelf registration statement filed with the SEC.

scPharmaceuticals Inc. (Nasdaq: SCPH) announced FDA marketing approval for FUROSCIX, a self-administered, subcutaneous diuretic for chronic heart failure treatments, marking a potential breakthrough in patient care. The company secured a $100 million debt financing agreement to aid commercialization efforts, with a planned launch in Q1 2023. Financially, third-quarter results showed a net loss of $10.2 million, while cash reserves decreased to $45.4 million. The adjusted net loss guidance for 2022 is now $38 to $41 million, a reduction from prior estimates.

scPharmaceuticals Inc. (Nasdaq: SCPH), a company focused on optimizing infused therapies, will have its President & CEO, John Tucker, present at the Jefferies London Healthcare Conference on November 16 at 5:35 pm GMT (12:35 pm ET). The event will be accessible via a live webcast in the Investor Relations section of their website. The company specializes in developing products to reduce healthcare costs and improve patient outcomes, particularly in heart failure and infectious diseases.

scPharmaceuticals Inc. (Nasdaq: SCPH) announced a conference call on November 9, 2022, at 4:30 p.m. ET to discuss third-quarter financial results and provide a business update. The call will be accessible via phone or through an audio webcast. The company focuses on optimizing infused therapies to enhance patient care and reduce healthcare costs, with key programs on subcutaneous, self-administered treatments for heart failure and infectious diseases.

scPharmaceuticals Inc. announced FDA approval for FUROSCIX (furosemide injection), designed for treating congestion in adults with Class II/III chronic heart failure. The unique formulation allows for subcutaneous administration at home via the On-Body Infusor, ensuring 99.6% bioavailability and comparable diuresis to intravenous treatments. FUROSCIX will be commercially launched in Q1 2023, addressing a significant market potential of $5.9 billion in the U.S. This innovation aims to reduce hospital admissions among heart failure patients, enhancing patient care and healthcare cost efficiency.

scPharmaceuticals Inc. (SCPH) announced a $100 million secured debt facility with Oaktree Capital Management to support the U.S. launch of FUROSCIX, approved by the FDA on October 7, 2022. The financing includes an immediate $50 million upon signing definitive agreements, with another $50 million contingent on meeting specific commercial milestones. The debt facility, with a capped interest rate of 11.75%, will enable the company to repay existing debt and facilitate its commercial launch efforts.

scPharmaceuticals (Nasdaq: SCPH) announced FDA approval for FUROSCIX®, a proprietary furosemide formulation for treating congestion due to fluid overload in adult patients with chronic heart failure (NYHA Class II/III). FUROSCIX, the first FDA-approved subcutaneous loop diuretic, offers IV-equivalent diuresis, allowing at-home administration via the On-Body Infusor, targeting a significant U.S. market of $5.9 billion. The commercial launch is set for Q1 2023, aiming to enhance patient care and reduce hospital admissions for over 7 million heart failure patients.

scPharmaceuticals Inc. (Nasdaq: SCPH) announced two poster presentations at the Heart Failure Society of America (HFSA) 2022 Annual Meeting, highlighting the clinical benefits of FUROSCIX® (furosemide injection) in treating heart failure congestion at home. Data from a pilot study showed that patients using FUROSCIX experienced significantly greater weight reduction and improved dyspnea scores compared to those on oral diuretics. The company anticipates a robust launch for FUROSCIX following its October 8 PDUFA date, pending FDA approval.